FDA recall Z-1312-2021

LumiraDx · Class II · device

Product

Coronavirus antigen detection test system - Product Usage: intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from nasal swab samples collected from individuals suspected of COVID-19 by their healthcare provider within the first twelve days of symptom onset.

Reason for recall

Two lots of test strips failed QC testing using blank buffer due to false positives.

Distribution

US nationwide distribution.

Key facts

Status
Terminated
Initiation date
2021-02-03
Report date
2021-04-07
Termination date
2022-07-13
Voluntary/Mandated
Voluntary: Firm initiated
Location
Waltham, MA, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=Z-1312-2021